



Press release  
2008-07-07

## **Tripep submits new application for phase II study of ChronSeal<sup>®</sup>**

Tripep has submitted a new application to the Medical Products Agency concerning the initiation of a Phase II study of ChronSeal<sup>®</sup>, a product owned jointly by Tripep and Kringle Pharma for the treatment of chronic leg wounds. The renewed application contains among other things supplementary information requested by the Medical Products Agency regarding the production of HGF (hepatocyte growth factor) in Japan. An independent inspection of the Japanese production facility has been performed as well as a revision of the study protocol. If approval is granted, it is estimated that the study will start during the fourth quarter of 2008.

### **For more information, please contact:**

Jan Nilsson, CEO, Tripep AB  
Tel: +46 8 449 84 80, mobile phone: +46 70 466 31 63  
E-mail: [jan.nilsson@tripep.se](mailto:jan.nilsson@tripep.se)

Anders Vahlne, Head of Research, Tripep AB  
Tel: +46 8 5858 1313, mobile phone: +46 709 28 05 28  
E-mail: [anders.vahlne@ki.se](mailto:anders.vahlne@ki.se)

#### *About Tripep*

*Tripep develops drugs against chronic disease based on proprietary and other parties' patented and patent pending technologies. Tripep is focusing on the following research projects; wound healing therapy ChronSeal<sup>®</sup> and a therapeutic vaccine against Hepatitis C, named ChronVac-C<sup>®</sup>, plus the RAS<sup>®</sup> technology platform. The Tripep share is admitted to trade on First North. Remium AB is Certified Adviser for Tripep AB. For more information, please refer to the company's website: [www.tripep.se](http://www.tripep.se).*

#### *About ChronSeal<sup>®</sup>*

*ChronSeal<sup>®</sup> is a HGF-based (Hepatocyte Growth Factor) treatment for chronic leg wounds, a rapidly increasing problem among the elderly population of the Western World. In cooperation with Tripep's partners Kringle Pharma and Zelmic AB, a new formulation has been developed that enables the use of ChronSeal<sup>®</sup> without it being combined with antibiotics. The new formulation allows for controllable release of HGF, thus avoiding antibiotic resistance, another rapidly growing problem. An application for a patent pertaining to an antibiotic-free formulation of ChronSeal<sup>®</sup> was filed in the US in January 2008.*

*More than four million people in the US and Europe are currently suffering from chronic leg wounds. According to Epsicom Business Intelligence this corresponds to a market value of approximately SEK 24 billion. Accordingly, the medical need is considerable and the growth rate is high, factors that are expected to provide ChronSeal<sup>®</sup> with substantial commercial potential.*